NCT01942733View on ClinicalTrials.gov

Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Sleep Disturbances
Interventions
DRUG

Brexpiprazole

2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT01942733 - Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter